Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
, 19 (1), 85-8

A Phase II Trial of 6-hydroxymethylacylfulvene (MGI-114, Irofulven) in Patients With Advanced Non-Small Cell Cancer Previously Treated With Chemotherapy

Affiliations
Clinical Trial

A Phase II Trial of 6-hydroxymethylacylfulvene (MGI-114, Irofulven) in Patients With Advanced Non-Small Cell Cancer Previously Treated With Chemotherapy

J E Dowell et al. Invest New Drugs.

Abstract

Purpose: To test the efficacy and safety of the novel antitumor agent MGI-114 (NSC 683863) in patients with advanced non-small cell lung cancer (NSCLC) previously treated with chemotherapy.

Methods: A two-stage accrual design was used to ensure detection of a true response rate of at least 20% with a type I error of .04. Eligible patients received 11 mg/m2 daily for five consecutive days. Cycles were repeated every 28 days.

Results: Fifteen patients received a total of 34 cycles of MGI-114. All patients had a performance status of 0 or 1. Eleven patients had previously received carboplatin and paclitaxel +/- radiation. Two patients had received cisplatin and CPT-11, one patient had received weekly paclitaxel, and one patient had received carboplatin and docetaxel. None of the first 15 patients enrolled experienced objective tumor response, and the study was closed. Forty percent of patients developed > or = grade 2 thrombocytopenia. Grade 3 nausea and > or = grade 2 vomiting were observed in 40% and 47% of patients respectively. Thirty-three percent of patients experienced > or = grade 2 fatigue.

Conclusions: MGI-114, at this dose and schedule, does not have significant activity as second line therapy for patients with advanced NSCLC.

Similar articles

See all similar articles

References

    1. Cancer Treat Rep. 1987 Nov;71(11):1079-85 - PubMed
    1. CA Cancer J Clin. 1999 Jan-Feb;49(1):8-31, 1 - PubMed
    1. Biochem Pharmacol. 1994 Jul 19;48(2):403-9 - PubMed
    1. Experientia. 1996 Jan 16;52(1):75-80 - PubMed
    1. Semin Oncol. 1994 Aug;21(4 Suppl 7):7-18 - PubMed

Publication types

MeSH terms

LinkOut - more resources

Feedback